Safety and Efficacy of IRAK4 Degrader KT-474 (SAR444656) for . . . KT-474 Achieved Robust and Sustained IRAK4 Degradation with Multiple Daily Oral Doses (14 Days) Absolute IRAK4 Levels • Detected by mass spectrometry in circulating PBMC • Steady state IRAK4 reduction achieved between Days 7 and 14 • Recovery towards baseline by Day 28 (2 weeks after last dose)
Kymera reports positive results from trial of IRAK4 degrader Kymera Therapeutics has reported positive results from a Phase I clinical trial of its lead programme, KT-474 (SAR444656), for the treatment of hidradenitis suppurativa (HS) and atopic dermatitis (AD)
Pharmacokinetics and Pharmacodynamics of KT-474, a Novel . . . - PubMed KT-474 demonstrated robust IRAK4 degradation in blood, with mean reductions of up to 98% observed at the 50-200 mg QD doses, as well as inhibition of ex vivo induction of a broad array of cytokines and chemokines by stimulants lipopolysaccharides and R848
Kymera Announces Positive Results from Phase 1 Clinical Trial . . . KT-474 Phase 1 clinical data in HS and AD patients demonstrate robust IRAK4 knockdown in blood and active skin lesions and systemic suppression of proinflammatory cytokines and chemokines with a favorable safety profile